Targeting the Wnt/β-catenin signaling pathway in human cancers

H Yao, E Ashihara, T Maekawa - Expert opinion on therapeutic …, 2011 - Taylor & Francis
Introduction: The Wnt/β-catenin signaling pathway plays a pivotal role in the regulation of
cell growth, cell development and the differentiation of normal stem cells. Constitutive …

Future prospect of RNA interference for cancer therapies

E Ashihara, E Kawata, T Maekawa - Current drug targets, 2010 - ingentaconnect.com
RNA interference (RNAi) is a phenomenon of sequence-specific gene silencing in
mammalian cells and its discovery has lead to its wide application as a powerful tool in post …

Targeting protein phosphatase PP2A for cancer therapy: development of allosteric pharmaceutical agents

DL Brautigan, C Farrington, G Narla - Clinical Science, 2021 - portlandpress.com
Tumor initiation is driven by oncogenes that activate signaling networks for cell proliferation
and survival involving protein phosphorylation. Protein kinases in these pathways have …

The choice dilemma in chronic hematological conditions: why choosing is not only a medical issue? A psycho-cognitive perspective

C Renzi, S Riva, M Masiero, G Pravettoni - Critical Reviews in Oncology …, 2016 - Elsevier
Research in cognitive psychology focused on risk perception and decision making was
shown to facilitate treatment choice and patient's satisfaction with decision in a number of …

Zoledronic acid-a multiplicity of anti-cancer action

T Yuasa, S Kimura, E Ashihara… - Current medicinal …, 2007 - ingentaconnect.com
Bisphosphonates (BPs) are inhibitors of bone-resorption and have become the current
standard of care for preventing skeletal complications associated with bone metastases …

Imatinib combined with mitoxantrone/etoposide and cytarabine is an effective induction therapy for patients with chronic myeloid leukemia in myeloid blast crisis

S Fruehauf, J Topaly, EC Buss, T Fischer… - … Journal of the …, 2007 - Wiley Online Library
BACKGROUND Despite advances in drug therapy and allogeneic stem cell transplantation
(allo‐SCT), the prognosis of patients with chronic myeloid leukemia (CML) in blast crisis …

Non-ATP competitive protein kinase inhibitors as anti-tumor therapeutics

LO Kirkland, C McInnes - Biochemical pharmacology, 2009 - Elsevier
Alternative approaches for inhibitor development in targeting sites other than the ATP cleft
are increasingly being pursued in the search for new therapeutics based on inhibition of …

[HTML][HTML] The Bcr-Abl kinase inhibitor INNO-406 induces autophagy and different modes of cell death execution in Bcr-Abl-positive leukemias

Y Kamitsuji, J Kuroda, S Kimura, S Toyokuni… - Cell Death & …, 2008 - nature.com
Bcr-Abl tyrosine kinase (TK) inhibitors are promising therapeutic agents for Bcr-Abl-positive
(Bcr-Abl+) leukemias. Although they are known to promote caspase-mediated apoptosis, it …

Targeting of leukemia-initiating cells to develop curative drug therapies: straightforward but nontrivial concept

P Valent - Current cancer drug targets, 2011 - ingentaconnect.com
The concept of leukemic stem cells (LSC) is increasingly employed to explain the biology of
various myeloid neoplasms and to screen for essential targets, with the hope to improve …

Intravesical administration of γδ T cells successfully prevents the growth of bladder cancer in the murine model

T Yuasa, K Sato, E Ashihara, M Takeuchi… - Cancer immunology …, 2009 - Springer
Background Superficial bladder cancers are usually managed with transurethral resection
followed by the intravesical administration of Bacillus Calmette-Guerin which requires major …